Authors

• Tatsuya Nagano (ORCID: https://orcid.org/0000-0003-0790-5139)
• Manabu Shigeoka (ORCID: https://orcid.org/0000-0003-1130-7166)
• Masaya Akashi (ORCID: https://orcid.org/0000-0003-0432-3299)
• Ratoe Suraya (ORCID: https://orcid.org/0000-0001-5210-0431)
• Takumi Hasegawa (ORCID: https://orcid.org/0000-0002-7349-7084)
• Yumi Muraki
• Yasumasa Kakei (ORCID: https://orcid.org/0000-0002-5997-514X)
• Daisuke Takeda (ORCID: https://orcid.org/0009-0000-5878-8871)
• Kaito Uryu
• Noriaki Emoto (ORCID: https://orcid.org/0000-0001-6673-2616)
• Akira Kimoto (ORCID: https://orcid.org/0000-0001-8757-0943)
• Tetsuya Hara
• T. Shirai

Institutions

• Kobe Pharmaceutical University (JP)
• Kobe University (JP)

Publication Details

Journal

Cancers

Published

2025-11-21

DOI

https://doi.org/10.3390/cancers17233732

Primary Topic

IL-33, ST2, and ILC Pathways

Type

article

Field-Weighted Citation Impact

0.00

Funders

• National Institute for Physiological Sciences